Zydus Lifesciences Secures FDA Approval for Generic Ammonium Lactate Cream for Dry Skin Conditions
核心洞察
Zydus Lifesciences received final FDA approval for Ammonium Lactate Cream (搜索) 12%, a generic version of Lac-Hydrin Cream (搜索) for treating xerosis (搜索) and ichthyosis vulgaris (搜索).
The topical prescription medication functions as both a moisturizer and alpha-hydroxy acid to increase skin hydration, relieve itching, and reduce scaling.
The approved product targets a market with annual sales of $15 million in the United States, expanding Zydus's dermatology portfolio to 430 total FDA approvals.
Zydus Lifesciences has secured final approval from the United States Food and Drug Administration (搜索) for Ammonium Lactate Cream (搜索), 12%, a generic version of Lac-Hydrin Cream (搜索). The approval represents the company's entry into a specialized dermatology market addressing chronic dry skin conditions.
Therapeutic Applications and Mechanism
The approved ammonium lactate cream (搜索) is indicated for treating dry, scaly skin (xerosis (搜索)) and ichthyosis vulgaris (搜索), an inherited dry skin condition. The medication operates through a dual mechanism, functioning both as a moisturizer to increase skin hydration and as an alpha-hydroxy acid that helps relieve itching, soften skin, and decrease skin scaling.
This topical prescription medication addresses significant unmet needs in dermatology care, particularly for patients with chronic dry skin conditions that require ongoing management and specialized treatment approaches.
Manufacturing and Distribution Strategy
Zydus will manufacture the ammonium lactate cream (搜索) at its topical manufacturing facility located in Changodar, Ahmedabad. The company has established Viona Pharmaceuticals Inc. as the distribution partner for the product in the United States market.
The manufacturing site selection demonstrates Zydus's commitment to leveraging its existing infrastructure for specialized dermatological products, ensuring quality control and supply chain efficiency for the U.S. market.
Market Opportunity and Portfolio Expansion
According to IQVIA data, ammonium lactate cream (搜索) generated annual sales of $15 million in the United States market as of December 2025. This approval allows Zydus to compete in the generic dermatology segment with an established product that addresses chronic skin conditions.
The approval brings Zydus's total FDA approvals to 430, reflecting the company's sustained growth in the U.S. generic pharmaceutical market. Since beginning its ANDA filing process in FY 2003-04, the company has filed 505 Abbreviated New Drug Applications, demonstrating a robust pipeline development strategy.
Regulatory Milestone
The final FDA approval represents a significant regulatory achievement for Zydus Lifesciences, validating the company's manufacturing capabilities and regulatory compliance standards. The approval process for topical dermatological products requires demonstration of bioequivalence and manufacturing quality standards equivalent to the reference listed drug.
This approval strengthens Zydus's position in the competitive U.S. generic pharmaceutical market, particularly in specialized therapeutic areas like dermatology where patient needs for effective, affordable treatments remain substantial.